These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29785088)

  • 41. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
    Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
    Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
    Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
    Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC.
    Luukkainen MEK; Koivunen JP
    Anticancer Res; 2024 Jul; 44(7):2805-2813. PubMed ID: 38925827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
    Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
    Serritella AV; Bestvina CM
    Thorac Surg Clin; 2020 May; 30(2):137-146. PubMed ID: 32327172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
    Ai X; Shen S; Shen L; Lu S
    Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
    Chuang YC; Huang BY; Chang HW; Yang CN
    Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
    Noé J; Lovejoy A; Ou SI; Yaung SJ; Bordogna W; Klass DM; Cummings CA; Shaw AT
    J Thorac Oncol; 2020 Apr; 15(4):601-608. PubMed ID: 31712133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Therapy With Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non-Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation.
    Usmani S; Marafi F; Rasheed R; Al Maraghy M; Al Kandari F
    Clin Nucl Med; 2018 Oct; 43(10):752-754. PubMed ID: 30059431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2017 Jun; 18(6):36. PubMed ID: 28534251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
    Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
    EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.
    Skoulidis F; Papadimitrakopoulou VA
    Clin Cancer Res; 2016 Nov; 22(21):5177-5182. PubMed ID: 27609840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
    Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
    Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
    Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
    Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
    Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
    J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.